14 completed, 4 unknown, 2 recruiting, 1 available. 11 Phase 2, 7 Phase 1, 3 Not applicable, 3 Phase 3, 1 Early Phase 1.
Follow EGCG: new trials by email Literature Review of EGCG trials Research Report on EGCG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reducing Frailty for Older Cancer Survivors Using Supplements II Epigallocatechin-3-Gallate (EGCG), Microcrystalline cellulose (MCC), Ascorbic Acid (Vitamin C) - Frailty, Inflammation | Phase 2 | Suspended | University of Rochester | 118 | 2024-10-25 | 2026-06-26 |
| Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance Curcumin, Epigallocatechin Gallate, Placebo - Mood Disturbance | Early Phase 1 | Recruiting | Auburn University | 64 | 2024-09-30 | 2025-02-14 |
| Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia EGCG - Pneumonia, Interstitial, Cancer Patients | Phase 2 | Completed | Shandong Cancer Hospital and Institute | 111 | 2023-06-05 | 2025-11-28 |
| Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients EGCG - Interstitial Pneumonia, Neoplasms Malignant | Phase 1 / Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 78 | 2023-01-05 | 2023-05-30 |
| The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III Vitamin D3 Drops, Coriolus Versicolor, Trident SAP 66:33 Lemon - Lung Cancer, Gastric Cancer | Phase 3 | Recruiting | Ottawa Hospital Research Institute | 20 | 2022-04-04 | 2026-01-30 |
| Study of Epigallocatechin-3-gallate (EGCG) for Supportive and Symptomatic Management in Patients With Esophageal Cancer EGCG - Esophageal Obstruction | Phase 1 | Completed | Shandong Cancer Hospital and Institute | 18 | 2021-08-20 | 2024-04-03 |
| Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal Intervention EGCG, Placebo EGCG, Healthy lifestyle recommendations - Alzheimer Disease, Cognitive Decline | Not applicable | Completed | Parc de Salut Mar | 129 | 2019-10-30 | 2024-03-15 |
| Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy EGCG, mLDG - Lung Neoplasms, Esophagitis | Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 83 | 2015-04-01 | 2020-04-28 |
| Effect of Epigallocatechin -3-gallate Supplementation in Traumatic Brain Injury Patients EGCG, Placebo (deionized water) - Traumatic Brain Injury | Phase 2 / Phase 3 | Completed | National Nutrition and Food Technology Institute | 30 | 2015-03-01 | 2016-06-07 |
| Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy EGCG, placebo - Breast Neoplasms, Dermatitis | Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 68 | 2014-12-01 | 2019-04-05 |
| "Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome" (TESFX) EGCG, Placebo, Cognitive training - Fragile X Syndrome | Phase 2 | Completed | Parc de Salut Mar | 44 | 2013-06-11 | 2019-05-10 |
| A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) Epigallocatechin-3-gallate (EGCG), Placebo - Light Chain (AL) Amyloidosis, Cardiac Involvement | Phase 2 | Completed | Florian Michel | 38 | 2013-04-01 | 2017-10-17 |
| Improvement of Endothelial Function by EGCG Green tea beverage, Green tea extract, EGCG - Cardiovascular Diseases | Not applicable | Completed | Charite University, Berlin, Germany | 50 | 2012-08-01 | 2016-02-03 |
| Study of Topically Applied Green Tea Extract for Radio Dermatitis and Radiation Mucositis EGCG - Epigallocatechin Gallate, Radio Dermatitis | Phase 1 / Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 15 | 2011-09-01 | 2020-04-28 |
| Effects of Green Tea Extract on Obese Women With High Level of LDL green tea extract, Placebo - Obese, Hyperlipidemia | Phase 3 | Completed | National Yang Ming Chiao Tung University | 73 | 2011-08-01 | 2014-04-17 |
| Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II Polyphenon E, Placebo - Multiple Sclerosis | Phase 2 | Terminated | Louisiana State University Health Sciences Center in New Orleans | 11 | 2011-07-01 | 2014-03-14 |
| Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals Polyphenon E, Placebo - HIV Infection | Phase 1 | Completed | Baylor College of Medicine | 23 | 2010-12-01 | 2023-05-19 |
| Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck Erlotinib, Green Tea Polyphenon E - Cancer of Head and Neck, Neoplasms, Head and Neck | Phase 1 | Completed | Emory University | 25 | 2010-03-01 | 2018-12-05 |
| Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C silymarin, green tea extract (EGCG) - Chronic Hepatitis C, Oxidative Stress | Phase 1 | Completed | University of North Carolina, Chapel Hill | 28 | 2009-11-01 | 2017-04-18 |
| Effects of Epigallocatechin Gallate (EGCG) in Healthy, Young Adults EGCG, Placebo - Cognitive Function, Mood | Phase 4 | Completed | Northumbria University | 32 | 2009-08-01 | 2012-04-13 |
Showing 20 of 24. Sign in to see all of them.
Obesity (3) · Inflammation (2) · Lung Diseases, Interstitial (2) · Lung Neoplasms (2) · Multiple Sclerosis (2) · Airway Obstruction (1) · Alzheimer Disease (1) · Amyloidosis (1) · Brain Injuries, Traumatic (1) · Breast Neoplasms (1) · Cardiovascular Diseases (1) · Cognitive Dysfunction (1) · Dermatitis (1) · Diabetes Mellitus, Type 2 (1) · Esophageal Neoplasms (1)
Shandong Cancer Hospital and Institute (7) · Louisiana State University Health Sciences Center in New Orleans (2) · Parc de Salut Mar (2) · Auburn University (1) · Baylor College of Medicine (1) · Charite University, Berlin, Germany (1) · Emory University (1) · Florian Michel (1) · National Nutrition and Food Technology Institute (1) · National Yang Ming Chiao Tung University (1) · Northumbria University (1) · Ottawa Hospital Research Institute (1) · University of Copenhagen (1) · University of Maryland, Baltimore (1) · University of North Carolina, Chapel Hill (1)
United States (8) · China (4) · Germany (2) · Spain (2) · Canada (1) · Denmark (1) · Iran (1) · Taiwan (1) · United Kingdom (1)
Ligang Xing, MD,PhD (2) · Andrew D Fruge, PhD (1) · Andrew Seely, MD, PhD, FRCSC (1) · Arne Astrup, Proffessor (1) · Chung-Hua Hsu, PhD, MD (1) · Crystal Haskell (1) · Dong M. Shin, MD (1) · Dugald Seely, ND, MSc (1) · Filiz Seeborg, MD, MPH (1) · Jesus F Lovera, MD (1) · Jesus F Lovera, MD, MSPH (1) · Jinming Yu, M.D. (1) · Kashif Munir, MD (1) · Ligang Xing, MD, PhD (1) · Mario Lorenz, PhD (1)
PMID 26298797, PMID 24444526, PMID 30400924, PMID 35648426, PMID 37620508, PMID 38632501, PMID 41549240, PMID 42760935
K23AT004433 (2), P50CA128613 (1), R21AT003892 (1), R21AT004673 (1)